Clinical trials
Liver Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting liver cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,775 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06488378RecruitingPhase 1
Axatilimab and olaparib for BRCA/PALB2-mutated breast cancer
This trial tests combining two drugs – axatilimab and olaparib (a PARP inhibitor) – for people with advanced HER2-negative breast cancer that carries a BRCA or PALB2 gene mutation. The goal is to see if this new combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06375187RecruitingPhase 1
GC203 TIL for advanced solid tumors
This trial tests an experimental TIL therapy (GC203) for people with advanced solid tumors who have no more standard options. Doctors will take a piece of your tumor, make it into a personalized cell treatment, and give it back to try to fight the cancer.
ShanghaiAges 18–75 - NCT06305962RecruitingEarly Phase 1
Radioactive drug for advanced PD-L1 positive solid tumors
This trial tests a radioactive medicine (177Lu-anti-PD-L1 sdAb) that delivers radiation to cancer cells with PD-L1 protein, which is found on some solid tumors. It is for people whose cancer has spread or come back after standard treatments.
Kingswood, New South WalesAges 18 years+ - NCT06238921RecruitingPhase 1/Phase 2
Study of two drugs and radiation for triple-negative breast cancer that spread to the brain
This trial tests adding the drugs sacituzumab govitecan and zimberelimab to targeted radiation therapy for people with triple-negative breast cancer that has spread to the brain. The goal is to see if this combination helps control the cancer longer.
Tampa, FloridaAges 18 years+ - NCT06216249RecruitingPhase 2
Flexible dosing of Lu-PSMA for advanced prostate cancer
This trial tests a flexible dosing schedule of a targeted radiation drug (Lu-PSMA) for men with metastatic prostate cancer that has stopped responding to hormone therapy and chemotherapy. It aims to see if adjusting the treatment schedule can improve outcomes while reducing side effects.
Los Angeles, CaliforniaAges 18 years+ - NCT06165302Recruiting
Exercise study for men with advanced prostate cancer
This trial tests whether a structured exercise program can help men with metastatic prostate cancer who are on hormone therapy. It looks at changes in cancer cells and overall well-being.
Baltimore, MarylandAges 18–80 - NCT06102902RecruitingPhase 1
New drug added to chemotherapy for BRAF-mutated colorectal cancer
This trial combines a new drug called ZEN003694 with two standard chemotherapy drugs (cetuximab and encorafenib) to see if it can help people with a specific type of colorectal cancer that has the BRAF V600E mutation. This mutation makes the cancer grow, and the new drug targets it, potentially making the treatment more effective.
Costa Mesa, CaliforniaAges 18 years+ - NCT06084481RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
Duarte, CaliforniaAges 18 years+ - NCT06058988RecruitingPhase 2
T-DXd for people with brain cancer
This trial tests a drug called Trastuzumab Deruxtecan (T-DXd) for people with brain tumors that are either glioblastoma or have spread from other cancers. Doctors will see if T-DXd can shrink tumors or slow their growth, and they will collect tumor tissue during surgery or biopsy to study how the drug works.
New York, New YorkAges 18 years+ - NCT05997017RecruitingPhase 2
Nab-sirolimus plus letrozole for advanced endometrial cancer
This trial tests a combination of two drugs—nab-sirolimus and letrozole—for people with advanced or returning endometrioid endometrial cancer. The goal is to see if this combination can shrink tumors or slow cancer growth.
Little Rock, ArkansasAges 18 years+ - NCT05945732Recruiting
Testing T-DXd or chemo for HER2-low or HR-positive breast cancer
This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.
GrazAges 18 years+ - NCT05914974Recruiting
Tracking inflammation changes during immunotherapy in gynecologic cancer
This trial looks at how a blood inflammation marker (CRP) changes when people with metastatic gynecologic cancers receive immunotherapy, sometimes together with palliative chemotherapy. The goal is to see patterns that may help doctors better understand and manage treatment responses to immunotherapy.
TübingenAges 18 years+ - NCT05766371RecruitingPhase 2
Immunotherapy plus targeted radiation for advanced prostate cancer
This study combines two treatments: pembrolizumab, which helps your immune system fight cancer, and a targeted radioactive medicine (177Lu-PSMA-617) that seeks out and damages prostate cancer cells. It may help men whose prostate cancer has spread despite initial hormone therapy.
San Francisco, CaliforniaAges 18 years+ - NCT05739981RecruitingPhase 1/Phase 2
Immunotherapy plus chemo for newly diagnosed advanced ovarian cancer
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
Baltimore, MarylandAges 18 years+ - NCT05660083RecruitingPhase 2
Study of alpelisib plus iNOS inhibitor with nab-paclitaxel
This Phase 2 trial tests whether a combination of medicines can shrink and control HER2-negative metaplastic breast cancer that cannot be removed with surgery (locally advanced) or has spread (metastatic). It may help people whose cancer has specific lab/pathology features, and it also checks safety and how well the treatment works in the body.
Bethesda, MarylandAges 18 years+ - NCT05657873RecruitingPhase 2
Targeted radiation for metastatic lung cancer with liver spread
This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).
Miami, FloridaAges 18 years+ - NCT05570253RecruitingPhase 2
SDX-7320 plus eribulin for metastatic triple-negative breast cancer
This Phase 2 study tests whether adding SDX-7320 to eribulin can work better for people with triple-negative metastatic breast cancer. It focuses on patients who have had prior chemotherapy and who also show signs of metabolic imbalance such as higher body weight or higher HbA1c.
Miami, FloridaAges 18 years+ - NCT05398380Recruiting
Liver transplant for colorectal liver cancer that can’t be removed
This trial studies liver transplantation for certain people with colorectal cancer that has spread only to the liver and cannot be removed with surgery. It aims to improve outcomes for carefully selected patients whose cancer is controlled on chemotherapy and who meet specific safety and scan requirements.
Barcelona, BarcelonaAges 18–70 - NCT05327465Recruiting
Exercise program for Black men on prostate hormone therapy
This trial tests whether a structured exercise program can improve heart and blood-vessel health in Black men receiving androgen deprivation therapy for prostate cancer. It may help your cardiovascular (heart) health and monitors safety during the program.
Boston, MassachusettsAges 18 years+ - NCT05296681RecruitingPhase 2
Probiotic trial to help irinotecan work better in metastatic colon cancer
This trial tests a “microbiome health” product (a probiotic-type supplement) to improve how well irinotecan chemotherapy works for people with metastatic colon cancer. It aims to support gut health so treatment can be delivered effectively.
Hamilton, New JerseyAges 18 years+ - NCT05274048RecruitingPhase 1
Neratinib plus antibody-drug for HER2-positive stomach or esophagus cancer
This early-phase trial tests neratinib together with an antibody-drug to treat advanced HER2-positive gastro-esophageal (stomach/esophagus) cancer that can’t be removed by surgery. It’s for people whose cancer has progressed after at least one HER2-targeted treatment, aiming to shrink tumors and improve outcomes.
Palo Alto, CaliforniaAges 18 years+ - NCT05285358RecruitingPhase 1
Aerosol chemo plus standard drugs for bile duct and gallbladder cancer
This trial tests a new way to give the drug paclitaxel directly into your belly as a mist, along with two standard chemo drugs given through your veins, for bile duct or gallbladder cancer that has spread to the lining of the belly. The goal is to see if this approach can better control the cancer in the belly.
Duarte, CaliforniaAges 18 years+ - NCT04789486RecruitingPhase 1/Phase 2
MR-guided radiation plus nanoparticles for central lung or pancreatic tumors
This early-phase study tests a new way to deliver focused radiation using MRI guidance and tiny particles, aiming to treat certain central lung tumors or locally advanced pancreatic cancer. It’s designed to see how safe it is and how well it can control these tumors.
Boston, MassachusettsAges 18 years+ - NCT04734730RecruitingPhase 2
Talazoparib plus hormone therapy for metastatic prostate cancer
This trial tests whether talazoparib added to standard hormone therapy (ADT), along with abiraterone, can better control metastatic prostate cancer that hasn’t progressed despite starting hormone treatment. It may help people live longer and delay cancer worsening.
Duarte, CaliforniaAges 18 years+
Hear when a new Liver Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,775 recruiting liver cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Lung Cancer (Locally Advanced or Metastatic)
- Locally Advanced Rectal Cancer
- Locally Advanced Cervical Cancer
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.